Previous close | 89.51 |
Open | 92.36 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 89.12 - 89.48 |
52-week range | 84.53 - 119.56 |
Volume | |
Avg. volume | 63,990 |
Market cap | N/A |
Beta (5Y monthly) | 0.38 |
PE ratio (TTM) | 0.16 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
RAHWAY, N.J., November 28, 2023--Merck Announces First-Quarter 2024 Dividend
RAHWAY, N.J., November 28, 2023--Merck’s V116 an Investigational 21-valent PCV Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50+
RAHWAY, N.J., & CAMBRIDGE, Mass., November 21, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. announced today that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Caraway Therapeutics for a total potential consideration of up to $610 million, including an undisclosed upfront payment as well as contingent milestone payments. The upfront payment will be expensed by Merck in t